

Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Getting to know you
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Meeting in a hotel lobby
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Calls from Africa
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Revisions, revisions, revisions...
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Fingers crossed
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Success!
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

It's been a hard day's night
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Time to panic
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Crunch time
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

It’s getting real
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Are we all set?
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Put your John Hancock here
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

V = Victory
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Let’s get ready to help
Lifesaving diagnosis
Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Word of mouth
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Let’s do this
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Friend or foe?
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Welcome on board accelopment
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

February-Fest?
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Can’t think on an empty stomach
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

To me, to you
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Finding the missing pieces
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Earlier than usual submission
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Prepare yourself
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Let’s click these genes
Click chemistry
Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Time for action
One health
The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Ready. Set. Go.
One health
The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Work never stops
One health
The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Submit!
One health
The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Hear me out
One health
The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

The key is preparation
One health
The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

State your case
One health
The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Success!
One health
The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

He found us on here
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

We’re set
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Sometimes you have to improvise
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Engaging the public
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

The search continues
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Uploading…
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Not quite there yet
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Round two
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Dotting the i’s, crossing the t’s
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Resubmission
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Success!
Organic light
It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

There’s more than banks here
Monitoring oxygen
Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

Aim for the (Euro)stars
Monitoring oxygen
Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

Long time no hear
Monitoring oxygen
Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

More partners, more possibilities
Monitoring oxygen
Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

This could work
Monitoring oxygen
Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

It’s submission deadline-day
Monitoring oxygen
Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

Ups and downs
Monitoring oxygen
Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

Ready, steady, GO!
Monitoring oxygen
Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.